Evidence map›Paper›PMID 41654488›Full record

ArticleNature communications2026

Hepatocytes functionally reprogrammed by KIAA1199-high colorectal cancer cells favour the accumulation of pro-metastatic Egr1

Lisha Li, Lei Zhao, Kui Cao, Peiyi Zhang, Guojie Xu, Jinge Zheng, Zhenyu Lin, Dandan Yu, Jinghua Ren, Jing Zhang and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lisha Li *Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lei Zhao *Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID 0000-0003-2876-4347
Kui Cao *Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Peiyi Zhang *Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Guojie XuCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jinge ZhengCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhenyu LinCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Dandan YuCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jinghua RenCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jing ZhangWuhan YZY Medical Science & Technology Co., Ltd, Wuhan, P.R. China.
Pengfei ZhouWuhan YZY Medical Science & Technology Co., Ltd, Wuhan, P.R. China.
Tao ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. taozhangxh@hust.edu.cn.ORCID 0000-0003-4018-3393
Dejun ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. zhangdejun@hust.edu.cn.ORCID 0000-0002-8623-5075

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82272711National Natural Science Foundation of China (National Science Foundation of China) 82272900National Natural Science Foundation of China (National Science Foundation of China) 82373050National Natural Science Foundation of China (National Science Foundation of China) 82573302
6 · The paper itself

Abstract

Colorectal cancer liver metastasis (CRLM) is a leading cause of mortality, driven by poorly defined molecular interactions within the hepatic niche. Here, we identify a distinct population of pro-metastatic Early Growth Response 1 (Egr1)

Indexed as

Colorectal NeoplasmsEarly Growth Response Protein 1HepatocytesLiver NeoplasmsNeutrophilsAnimalsCell Line, TumorFemaleHumansMetabolic ReprogrammingMicePPAR gammaSignal TransductionEarly Growth Response Protein 1EGR1 protein, humanPPAR gamma

Identifiers

PMID41654488
PMCPMC12992918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.